Home
Home
  • Home
  • About Us About Us
    • Overview
    • Who we are
    • Why we provide advice
    • What are health technologies
    • Meetings
    • News
    • Who we work with
    • Contact Us
  • What We Do What We Do
    • Overview
    • Our Strategy
    • Work programme
    • Range of advice products
    • Quarterly Bulletin of advice
    • Early HTA Advice Service
  • Our Advice
  • Request Advice Request Advice
    • Overview
    • Form for requesting advice
  • Get Involved Get Involved
    • Overview
    • Contribute to advice
    • NHS boards
    • Patient and Public Involvement
    • Industry Involvement
    • Observe a council meeting
    • DOI Form

Evidence Synthesis

  • Home
  • Our Advice
  • Multiplex polymerase chain reaction gastrointestinal pathogen panels for people with suspected gastroenteritis

Title

Output Type

Speciality

Published

Title

Multiplex polymerase chain reaction gastrointestinal pathogen panels for people with suspected gastroenteritis

Output Type

Evidence Synthesis

Speciality

Digestive System, Infectious disease

Published

27 September 2019

Key findings

The evidence base consisted of one good quality systematic review (23 observational studies of poor quality) and a further four non-UK observational studies published since the NICE diagnostic guidance in 2017.

Due to observational study designs, the overall evidence is not robust and data on morbidity, mortality and quality of life outcomes is lacking Integrated GPPs demonstrate consistently faster turnaround time than conventional tests, which may be associated with improved antibiotic use and reduced requirement for additional diagnostic tests. Testing using GPPs did not affect length of hospital stay compared with conventional methods.

There is substantial uncertainty around the probability of cost effectiveness due to lack of clarity on the diagnostic accuracy of GPPs and the absence of patient outcome data.

  • In hospitalised adults, children and people who are immunocompromised, the probability of cost effectiveness of GPPs (Luminex xTAG® and Biofire FilmArray™ is around 54-58% compared with conventional testing.
  • In the recently returned from travel population and for patients in community settings the probability of cost effectiveness varied widely between the Luminex xTAG® GPP (99-100% probability) and the Biofire FilmArray™GPP (6% probability) compared with conventional testing. PCR tests could be useful as preliminary screening tests, particularly in the case of potential outbreaks of harmful infectious pathogens, such as Shiga-toxin producing E.coli. Positive PCR results should be confirmed by culture.

More robust evidence on clinical effectiveness may become available following completion of ongoing randomised controlled trials (RCTs). One UK study is due to be completed in September 2020 (GastroPOC). A US study is due to be completed in November 2019 (NCT03809117).

What were we asked to look at?

We were asked to examine the evidence on testing with multiplex polymerase chain reaction (PCR) gastrointestinal pathogen panels (GPPs) compared with conventional testing methods in people with suspected gastroenteritis.

Why is this important?

Conventional testing comprises multiple tests, such as immunoassay and stool culture, which can take several days to return results. Multiplex PCR GPP tests return results within hours. A faster diagnosis has implications for improved cost effectiveness and patient management outcomes, such as reduction in empirical antibiotic prescribing, length of hospital stay and use of isolation bays. Rapid detection of infectious pathogens can also limit and prevent outbreaks.

Referred by

The Scottish Microbiology and Virology Network (SMVN)

Download icon
Download Advice
pdf (413 KB)

Connect with Us

Please let us know if you'd like to receive regular updates on our work.


Last Updated: 31 January 2022

Scottish Health Technologies Group

© 2021, All rights reserved

  • Accessibility
  • Respecting your privacy
  • Cookies
  • Healthcare Improvement Scotland Website
  • Find us on Twitter
  • Freedom of Information

Tell us what you think


We'd love to hear your views

Was our advice useful?  Did you find what you were looking for on our website?